Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The firm is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The firm has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
106
103
156
98
295
88
Revenue Growth (YoY)
-34%
-34%
59%
-67%
235%
-41%
Cost of Revenue
1
0
3
10
3
2
Gross Profit
105
102
153
87
292
85
Selling, General & Admin
63
71
78
81
76
59
Research & Development
105
155
234
186
178
142
Operating Expenses
168
227
313
267
254
201
Other Non Operating Income (Expenses)
-19
5
0
12
5
-1
Pretax Income
-39
-232
-257
-230
-28
-182
Income Tax Expense
--
--
--
--
--
--
Net Income
-35
-227
-245
-220
-24
-181
Net Income Growth
-85%
-7%
11%
817%
-87%
69%
Shares Outstanding (Diluted)
32.85
21.47
17.89
14.08
11.44
8.62
Shares Change (YoY)
52%
20%
27%
23%
33%
28%
EPS (Diluted)
-1.07
-10.59
-13.75
-15.64
-2.11
-21
EPS Growth
-90%
-23%
-12%
641%
-90%
31%
Free Cash Flow
-89
-158
-234
-228
-23
-142
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
99.05%
99.02%
98.07%
88.77%
98.98%
96.59%
Operating Margin
-58.49%
-120.38%
-102.56%
-183.67%
12.54%
-131.81%
Profit Margin
-33.01%
-220.38%
-157.05%
-224.48%
-8.13%
-205.68%
Free Cash Flow Margin
-83.96%
-153.39%
-150%
-232.65%
-7.79%
-161.36%
EBITDA
-50
-111
-147
-174
43
-109
EBITDA Margin
-47.16%
-107.76%
-94.23%
-177.55%
14.57%
-123.86%
D&A For EBITDA
12
13
13
6
6
7
EBIT
-62
-124
-160
-180
37
-116
EBIT Margin
-58.49%
-120.38%
-102.56%
-183.67%
12.54%
-131.81%
Effective Tax Rate
--
--
--
--
--
--
Follow-Up Questions
What are Agenus Inc's key financial statements?
According to the latest financial statement (Form-10K), Agenus Inc has a total asset of $226, Net loss of $-227
What are the key financial ratios for AGEN?
Agenus Inc's Current ratio is 0.4, has a Net margin is -220.38, sales per share of $4.79.
How is Agenus Inc's revenue broken down by segment or geography?
Agenus Inc largest revenue segment is Non-cash Royalties, at a revenue of 100,978,000 in the most earnings release.For geography, United States is the primary market for Agenus Inc, at a revenue of 101,460,000.
Is Agenus Inc profitable?
no, according to the latest financial statements, Agenus Inc has a net loss of $-227
Does Agenus Inc have any liabilities?
yes, Agenus Inc has liability of 552
How many outstanding shares for Agenus Inc?
Agenus Inc has a total outstanding shares of 23.63
